Cardiovascular disease: what Cheongdam Cell Clinic states about stem cells

Cardiovascular disorder appears among the age-related conditions Cheongdam Cell Clinic mentions on its 淸(Rejuvenation)CELL programme page, alongside hypertension, diabetes and hyperlipidaemia, with the clinic framing all of them as connected through age-related decline in vascular health.

'Cardiovascular disorder' covers a broad range of conditions, from coronary artery disease to heart failure to arrhythmia, each with very different severity and treatment approaches. Stating that 'stem cells treat cardiovascular disorder' without specifying the condition is therefore too broad a claim to guide real clinical decisions.

Medically, stem-cell research for heart conditions such as post-heart-attack recovery has been ongoing since the 2000s, but results remain largely inconsistent and have not been adopted as standard treatment by major international cardiology societies. Accepted treatment remains medication, angioplasty, bypass surgery, or pacemaker/defibrillator implantation as indicated.

Cheongdam Cell Clinic does not describe itself as a specialised cardiac hospital, and its website gives no indication of a dedicated cardiology department or advanced diagnostic tools such as cardiac catheterisation. Anyone with chest pain, breathlessness or abnormal palpitations should see a cardiologist at a full-service hospital first, rather than starting the diagnostic process at a beauty or anti-ageing clinic.

If a cardiac patient with stable symptoms already under a cardiologist's care is interested in the 淸(Rejuvenation)CELL programme for general vascular support, they should bring their treatment history, cardiac test results (such as echocardiogram or EKG) and medication list for Cheongdam Cell Clinic's doctors to review, so the risk of stem-cell injection can be assessed as carefully as possible.

Many cardiovascular conditions relate to blood clotting and circulation. Any intravascular injection in patients with unstable cardiac status requires particularly careful risk consideration. Patients should ask the clinic directly whether specific contraindications apply to their cardiac condition before deciding.

Thai patients with heart disease considering travel to Seoul for this programme should first consult a cardiologist in Thailand about whether their current condition is suitable for long-distance travel and an elective supplementary procedure, since long travel itself carries risk for some cardiac patient groups.

In summary, Cheongdam Cell Clinic's cardiovascular-related programme should be viewed as general vascular-health support for patients with stable conditions, not a direct cardiac treatment, and it should not replace regular cardiology follow-up.